Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Prescription Drugs & Other Medical Products

Reports

Displaying 1 - 10 of 133. 10 per page. Page 1.

Advanced Search
ASPE Data Point

Insulin Affordability and the Inflation Reduction Act: Medicare Beneficiary Savings by State and Demographics

January 24, 2023
Effective January 1, 2023, out-of-pocket costs for insulin are capped at $35 per monthly prescription among Medicare Part D enrollees under the Inflation Reduction Act (IRA). A similar cap takes effect in Medicare Part B on July 1, 2023.
ASPE Issue Brief

COVID-19 Antivirals Utilization: Geographic and Demographic Patterns of Treatment in 2022

December 23, 2022
This report examines the utilization of oral antiviral medications, Paxlovid and Lagevrio, for the treatment of COVID-19. The analyses include an examination of time trends of COVID-19 antiviral use as well as breakdowns by age cohorts and gender. The report finds that utilization in the U.S.
Report to Congress

Report to Congress on the Affordability of Insulin

December 16, 2022
This Report to Congress examines the critical role that insulin plays in the treatment of diabetes, reviews evidence on how insulin affordability affects adherence to insulin treatment and affects downstream health consequences, and describes policy efforts to improve the affordability of insulin.
Research Brief

Early Changes in Waivered Clinicians and Utilization of Buprenorphine for Opioid Use Disorder After Implementation of the 2021 HHS Buprenorphine Practice Guidelines

December 2, 2022
In April 2021 the U.S. Department of Health and Human Services (HHS) issued revised Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder (Practice Guideline).
Research Brief

Meeting Substance Use and Social Service Needs in Communities of Color

November 23, 2022
In this brief, we highlight experiences and practices from substance use treatment providers and their human services partners when serving people of color. We selected providers that focused on serving people of color, and this study was not intended to assess outcomes or effectiveness of any of the practices highlighted.
Fact Sheet

Addressing the Opioid Overdose Crisis Through Better Data: Opioids Vignette

November 23, 2022
This updated 2022 vignette provides examples of how a range of Office of the Secretary Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) cross-agency projects are working to address the opioid overdose crisis by 1) Improving Timeliness and Quality of Outcomes Data 2) Building Capacity for Collection of Patient-Reported Outcomes 3) Building Linkages to Address Co-Morbidities
ASPE Issue Brief

National and State Estimates of Children Living with Parents Using Substances, 2015–2019

November 14, 2022
This brief presents estimates of the number and percentage of children whose parents engage in problematic substance use, including past-year substance use and SUD by substance type and child demographics. Key findings include:
Report

Certified Community Behavioral Health Clinics (CCBHC) Demonstration Program

November 3, 2022
Per Section 223(d)(7)(A) of the Protecting Access to Medicare Act (PAMA) of 2014 (Public Law 113-93), the HHS Secretary must submit to Congress an annual report on the use of funds provided under all demonstration programs conducted under this subsection, not later than one year after the date on which the first state is selected for a demonstration program under this subsection, and annually t
ASPE Issue Brief

Trends in Prescription Drug Spending, 2016-2021

September 30, 2022
High prescription drug costs are a leading concern among Americans. Americans pay higher prices for prescription drugs than any other country in the world, with prescription drug prices in the U.S. more than 2.5 times as high as those in other similar high-income nations.

Price Increases for Prescription Drugs, 2016-2022

September 30, 2022
Prescription drug price increases create affordability challenges for patients and for the government. This report tracks drug price changes from 2016-2022. There were 1,216 products whose price increases during the twelve-month period from July 2021 to July 2022 exceeded the inflation rate of 8.5 percent for that time period. The average price increase for these drugs was 31.6 percent.